Mochida Pharmaceutical Co., Ltd. (JP:4534)
:4534
Top Page
Mochida Pharmaceutical Co., Ltd.
(4534)
Select Model
Select Model
Rating:73Outperform
Price Target:
¥3,988.00
▲(10.32% Upside)
Action:UpgradedDate:11/15/25
Mochida Pharmaceutical's strong financial stability and profitability are key strengths, supported by positive technical momentum. However, challenges in revenue growth and cash flow volatility, along with a moderate valuation, limit the overall score. The absence of earnings call insights and corporate events does not impact the evaluation.
Positive Factors
Low leverage / strong balance sheet
Very low leverage provides durable financial flexibility: it reduces refinancing risk, supports continued R&D and licensing activity, and allows the company to absorb revenue volatility without stressing solvency. This underpins long-term strategic optionality and credit resilience.
Negative Factors
Declining revenue growth
A prolonged decline in revenue growth is a structural concern: it reduces scale economics, limits R&D and marketing budgets, and increases reliance on a narrower product set. Without new approvals or successful in-licensing, sustained top-line weakness can pressure future profitability and market position.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low leverage provides durable financial flexibility: it reduces refinancing risk, supports continued R&D and licensing activity, and allows the company to absorb revenue volatility without stressing solvency. This underpins long-term strategic optionality and credit resilience.
Read all positive factors
Mochida Pharmaceutical Co., Ltd. (4534) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥119.10B
Dividend Yield2.34%
Average Volume (3M)34.37K
Price to Earnings (P/E)12.6
Beta (1Y)0.65
Revenue Growth4.35%
EPS Growth48.30%
CountryJP
Employees1,522
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)70.12
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)0.86
Price to Sales (P/S)1.07
P/FCF Ratio15.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.3
Revenue Forecast (FY)¥110.00B
Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticanc...
How the Company Makes Money
Mochida Pharmaceutical makes money primarily by selling pharmaceutical products, with revenue largely generated from prescription drug sales in the domestic Japanese market. Its core revenue model includes (1) product sales from its own marketed p...
Mochida Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 106.38B | 105.16B | 102.89B | 103.26B | 110.18B | 103.00B |
| Gross Profit | 54.46B | 53.79B | 52.07B | 55.12B | 59.55B | 54.79B |
| EBITDA | 11.44B | 11.07B | 8.61B | 11.18B | 17.08B | 14.75B |
| Net Income | 6.03B | 5.68B | 4.55B | 6.65B | 10.57B | 8.59B |
Balance Sheet | ||||||
| Total Assets | 161.74B | 163.56B | 162.30B | 161.04B | 165.93B | 165.88B |
| Cash, Cash Equivalents and Short-Term Investments | 54.69B | 51.15B | 46.79B | 60.51B | 61.91B | 63.49B |
| Total Debt | 830.00M | 342.00M | 369.00M | 178.00M | 0.00 | 0.00 |
| Total Liabilities | 30.59B | 32.87B | 34.33B | 34.26B | 37.28B | 38.90B |
| Stockholders Equity | 131.15B | 130.69B | 127.97B | 126.78B | 128.65B | 126.97B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 7.19B | -9.78B | 5.13B | 4.47B | 7.26B |
| Operating Cash Flow | 0.00 | 9.35B | -7.48B | 7.30B | 7.46B | 9.20B |
| Investing Cash Flow | 0.00 | 17.36B | 74.00M | -2.95B | -2.01B | -880.00M |
| Financing Cash Flow | 0.00 | -2.87B | -6.39B | -6.88B | -5.96B | -5.11B |
Mochida Pharmaceutical Co., Ltd. Technical Analysis
Negative
3615.00
Price Trends
3629.56
Negative
3523.51
Negative
3276.30
Positive
Market Momentum
-38.47
Positive
45.77
Neutral
28.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Negative. The current price of 3615 is above the 20-day moving average (MA) of 3534.86, below the 50-day MA of 3629.56, and above the 200-day MA of 3276.30, indicating a neutral trend. The MACD of -38.47 indicates Positive momentum. The RSI at 45.77 is Neutral, neither overbought nor oversold. The STOCH value of 28.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4534.
Mochida Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥150.92B | 93.62 | -2.58% | 4.16% | -5.99% | -96.04% | |
79 Outperform | ¥194.84B | 14.92 | 6.70% | 2.48% | 13.11% | 41.57% | |
73 Outperform | ¥119.10B | 12.60 | 4.81% | 2.34% | 4.35% | 48.30% | |
69 Neutral | ¥89.22B | 8.41 | ― | 3.36% | 11.65% | 93.46% | |
67 Neutral | ¥211.87B | 5.05 | 12.02% | 2.14% | 9.32% | 30.85% | |
59 Neutral | ¥224.06B | 13.89 | ― | 2.28% | 12.78% | -105.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,500.00
539.18
18.21%
JP:4521
Kaken Pharmaceutical Co
4,190.00
17.95
0.43%
JP:4547
Kissei Pharmaceutical Co
4,770.00
1,220.69
34.39%
JP:4553
Towa Pharmaceutical Co
4,305.00
1,871.54
76.91%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,695.00
316.72
22.98%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
2,252.50
385.37
20.64%
Mochida Pharmaceutical Co., Ltd. Corporate Events
Mochida Pharmaceutical Sets Terms for Secondary Share Offering and Over-Allotment
Apr 6, 2026
Mochida Pharmaceutical has set the terms for a secondary offering of its common stock, establishing an offer price of 3,331 yen per share for shares to be purchased and underwritten by the underwriters, with a total offer value of approximately 3....
Mochida Pharma Clears Audit Review as Profits Rise Ahead of Secondary Share Offering
Mar 30, 2026
Mochida Pharmaceutical said an independent auditor has completed its interim review of the consolidated financial statements for the nine months ended Dec. 31, 2025, clearing the way for a previously approved secondary offering of common shares. T...
Mochida Pharmaceutical Unveils Up to ¥2 Billion Share Buyback Plan
Mar 30, 2026
Mochida Pharmaceutical Co., Ltd. has approved a share repurchase program authorizing the buyback of up to 530,000 shares of its common stock, representing about 1.50% of its outstanding shares excluding treasury stock. The maximum total purchase a...
Mochida Pharmaceutical Plans Secondary Share Offering to Boost Liquidity
Mar 30, 2026
Mochida Pharmaceutical will conduct a secondary offering of 1,153,600 existing common shares through a purchase and underwriting arrangement, with pricing to be set in early April based on market demand and recent Tokyo Stock Exchange trading leve...
Mochida to Acquire Full Rights to URECE Gout Drug from Fuji Yakuhin
Mar 30, 2026
Mochida Pharmaceutical has agreed to take over the manufacturing and marketing approval for URECE Tablets, a dotinurad-based treatment for gout and hyperuricemia, from FUJI YAKUHIN in Japan and to acquire associated assets including patents and tr...
Mochida Pharmaceutical Lifts Nine-Month Earnings and Raises Full-Year Profit Forecast
Feb 6, 2026
For the nine months ended December 31, 2025, Mochida Pharmaceutical reported an 8.4% year-on-year rise in consolidated net sales to ¥87.5 billion, with operating profit up 3.9% to ¥7.5 billion and profit attributable to owners of parent ...
Mochida Pharmaceutical Raises Full-Year Earnings Forecast on Strong Core Business
Feb 6, 2026
Mochida Pharmaceutical has raised its full-year consolidated forecast for the fiscal year ending March 31, 2026, reflecting stronger-than-expected performance in its pharmaceutical business and higher income from equity-method investments. The com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.